Affimed NV (NASDAQ:AFMD) – Stock analysts at Jefferies Financial Group upped their FY2020 EPS estimates for Affimed in a research note issued on Monday, November 5th. Jefferies Financial Group analyst M. Raycroft now forecasts that the biopharmaceutical company will post earnings of $0.55 per share for the year, up from their prior estimate of ($0.75). Jefferies Financial Group currently has a “Buy” rating and a $4.00 price objective on the stock. Jefferies Financial Group also issued estimates for Affimed’s FY2021 earnings at ($0.62) EPS and FY2022 earnings at $1.03 EPS.

A number of other analysts have also recently weighed in on AFMD. BMO Capital Markets decreased their target price on shares of Affimed from $6.00 to $4.00 and set an “outperform” rating on the stock in a research note on Thursday, August 9th. ValuEngine upgraded shares of Affimed from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 28th. BidaskClub upgraded shares of Affimed from a “strong sell” rating to a “sell” rating in a report on Friday, August 31st. Zacks Investment Research upgraded shares of Affimed from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a report on Tuesday, October 9th. Finally, SunTrust Banks lowered their target price on shares of Affimed to $5.00 and set a “buy” rating on the stock in a report on Thursday, October 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $4.81.

Shares of NASDAQ:AFMD opened at $4.06 on Thursday. The company has a market capitalization of $247.07 million, a P/E ratio of -5.21 and a beta of 3.62. The company has a current ratio of 5.36, a quick ratio of 5.33 and a debt-to-equity ratio of 0.06. Affimed has a 1 year low of $1.15 and a 1 year high of $7.35.

Affimed (NASDAQ:AFMD) last released its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). Affimed had a negative net margin of 2,124.72% and a negative return on equity of 77.87%. The business had revenue of $0.36 million during the quarter, compared to analyst estimates of $0.30 million.

Institutional investors have recently bought and sold shares of the company. CIBC World Markets Inc. bought a new position in shares of Affimed during the 3rd quarter valued at $104,000. Stanley Laman Group Ltd. bought a new stake in Affimed in the 2nd quarter worth $100,000. Barclays PLC grew its holdings in Affimed by 385.3% in the 1st quarter. Barclays PLC now owns 64,958 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 51,573 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of Affimed during the 2nd quarter valued at about $165,000. Finally, EAM Investors LLC bought a new stake in shares of Affimed during the 3rd quarter valued at about $656,000. Hedge funds and other institutional investors own 40.62% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Read More: Short Selling Stocks and Day Traders

Earnings History and Estimates for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.